key: cord-0291433-85j4fyam authors: Gazit, S.; Mizrahi, B.; Kalkstein, N.; Neuberger, A.; Peretz, A.; Mizrahi-Reuveni, M.; Patalon, T. title: BNT162b2 mRNA Vaccine Effectiveness Given Confirmed Exposure; Analysis of Household Members of COVID-19 Patients date: 2021-07-03 journal: nan DOI: 10.1101/2021.06.29.21259579 sha: e20e310ee54d03515a4c425f00d65724c1d3aeb8 doc_id: 291433 cord_uid: 85j4fyam Importance While the mRNA BNT162b2 vaccine effectiveness was demonstrated in general population, the question of effectiveness given confirmed exposure has yet been answered, though it has policy implications, as the need for self-quarantine when exposed and protective measures for vaccinated in high-risk areas. Objective Assessing the BNT162b2 vaccine effectiveness in preventing SARS-CoV-2 infection given high-risk exposure, through analysis of household members of confirmed cases. Design Retrospective cohort study. Data of household members of confirmed SARS-CoV-2 cases between 20/12/2020 and 17/03/2021 were collected. Setting Nationally centralized database of Maccabi Healthcare Services (MHS), the second largest Healthcare Maintenance Organization in Israel. Participants 2.5 million MHS members were considered, of which we included only households with two adult members, given possible lower transmission and susceptibility among children. Households with no prior confirmed infections and a confirmed index case during the study period were included. Exposure Participants were classified into three vaccination groups in time of the index case (the confirmed exposure)- Unvaccinated; Fully Vaccinated(7 or more days post second dose) and a reference control group of Recently Vaccinated Once(0-7 days from the first dose, presumably still unprotected). Main Outcomes and Measures Assessing the probability of an additional SARS-CoV-2 infection in the household occurring within 10 days of an index case, calculated separately for the three vaccination groups. Main outcome was vaccine effectiveness given confirmed exposure. High testing rates among household members enabled us to estimate with a high degree of confidence effectiveness against asymptomatic SARS-CoV-2 infection as well. Results A total of 173,569 households were included, out of which 6,351 households had an index infection (mean [SD] age, 58.9 [13.5] years; 50% were women). Vaccine effectiveness of Fully Vaccinated compared to Unvaccinated participants was 80.0% [95% CI, 73.0-85.1] and 82.0% [95% CI, 75.5-86.7] compared to those Recently Vaccinated Once. Conclusion and Relevance The BNT162b2 vaccine is effective in a high-risk, real life, exposure scenario, but the protection rates afforded in these settings are lower than those previously described. Household members of COVID-19 patients and any individual with a confirmed exposure to COVID-19 are still at a considerable risk of being infected even if fully vaccinated. During the COVID-19 pandemic, policymakers are required to make decisions based on incomplete data in an ever-changing environment 1, 2 . Any assessment of the effect of the vaccine on community transmission by use of observational data is complicated by two factors. Firstly, the probability of an individual to be infected is greatly influenced by personal behavior and transmission rates in that individual's immediate surroundings; secondly, the probability of a person to be tested for COVID-19 depends on multiple factors, such as education level or testing availability 3 -and often on the existence of symptoms. Using data obtained from the computerized database of the Maccabi Healthcare Services (MHS), the second largest Healthcare Maintenance Organization (HMO) in Israel, we tried to overcome these two potential biases. We analyzed household contacts of confirmed COVID-19 cases, thereby solely including a population at a very high risk of contracting COVID-19 [4] [5] [6] [7] . Thus, we essentially examined vaccine effectives given confirmed exposure; comparing those exposed (whether in the household or in the community) but not infected to those exposed (whether in the household or in the community) -and infected, across vaccination statuses. In addition, the probability of a person to be tested for COVID-19 when a household member had already been infected was extremely high in Israel during the study period, therefore allowing for a closer approximative analysis of asymptomatic infection, often not tested and therefore underdiagnosed -potentially impacting the vaccine effectiveness analyses published thus far. In Israel, a large-scale vaccination program was initiated on December 20, 2020, well before similar efforts were undertaken in other countries 8 . Since within a period of ten weeks more than All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259579 doi: medRxiv preprint 6 50% of the population in Israel was vaccinated with the BNT162b2 9 , data are now available for the analysis of the effectiveness of the vaccine in the prevention of transmission among those at the highest risk of infection, namely household contacts of confirmed COVID-19 cases 10 . We performed an observational cohort study that included household members of confirmed COVID-19 cases, and estimated the effectivness of the mRNA BNT162b2 vaccine vaccine in this high-risk setting. Participants were considered for inclusion from 20/12/2020 onwards, corresponding to the starting date of the national COVID-19 vaccination rollout program. The occurrence of a first episode of infection was recorded up to March 8, 2021 ; by this time roughly 50% of the entire Israeli population had been vaccinated. Additional household infections were recorded for ten extra days, until March 17, 2021. In Israel all citizens are insured by one of four HMOs as part of a national medical insurance scheme, of which MHS is the second largest with roughly 2.5 million members. For the purpose of this analysis, a household was defined as having two adults. Only households with two adults were included so the protective effect of vaccination could be assessed in a relatively homogenous adult population, given reports of both lower transmission and lower susceptibility in children 12 . Additionally, including more than two members in a household would have required a correction for the number of 'individuals at risk' as well as for 'degree of exposure'. See more in the limitations part of the discussion. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 7 Households with no confirmed COVID-19 infections prior to the study period, with a confirmed index case diagnosed during the study period and with one additional adult who is a member Once, was chosen as a reference period, when the vaccination protective effect is presumably still insignificant (as opposed to persons more than 12 days after the 1 st vaccine, when some protection does probably exist) 11 . This enabled us to compare persons who chose to be vaccinated and were either fully protected or not protected at all, and thus to control for possible inherent differences between those who chose not to be vaccinated at all. COVID-19 was diagnosed with the use of nationally approved SARS-CoV-2 polymerase-chainreaction (PCR) testing kits. The study's primary outcome was COVID-19 infection within ten days of COVID-19 diagnosis in an additional adult member of the same household (where an index infection occurred). Both index and additional cases were defined by at least one positive SARS-CoV-2 polymerase chain reaction (PCR) test recorded in the MHS computerized database, considering that all such testing in MHS members is recorded centrally. Household members of confirmed cases were considered not infected if all PCR tests were negative or if no COVID-19 testing was performed. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259579 doi: medRxiv preprint The MHS databases were used for this study. As annual disengagement rates are lower than 1%, longitudinal data are available for nearly all persons insured in the MHS. We used existing demographic and background medical data. COVID-19 tests and performance dates were recorded for each patient, as were the dates of the first and second BNT162b2 vaccine administration. We assessed the probability of a COVID-19 infection occurring up to 10 days after a previously diagnosed COVID-19 infection in a given household. The probability of being infected was calculated separately for the three vaccination status groups, namely the unvaccinated, those vaccinated within 0-7 days of the first dose of the vaccine, and the fully vaccinated. For the primary endpoints, vaccine effectiveness was defined for Unvaccinated versus Fully Vaccinated and Unvaccinated versus Recently Vaccinated Once as one minus the risk ratio. Individuals differ in their decision be tested for COVID-19. Their vaccination status, perceived risk of infection, and symptomatology could all effect this decision 13 . Furthermore, the Israeli Ministry of Health's regulations indicating that fully vaccinated persons were not obliged to exercise self-quarantine when exposed to a confirmed COVID-19 individual, may have affected the likelihood of vaccinated persons to be tested after an exposure. We hence carried out a All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259579 doi: medRxiv preprint 9 secondary analysis attempting to account for differing testing behavior possibly resulting in missed COVID-19 diagnoses. We calculated corrected vaccine effectiveness rates assuming that untested individuals were as likely to be infected as tested ones. Therefore, we calculated a corrected effectiveness rate, simulating a scenario in which 100% of adult household members are tested, under the assumption that the probability of test positivity remains constant (rather than decreases in untested individuals). This analysis intends to demonstrate the least-favorable (or strictest) scenario for vaccine effectiveness, enabling us to estimate lower bound efficiency. Our final tier of analyses addressed the problem of defining an "index" infection as opposed to an "additional" infection, in light of a known time lag between the infection event and its detection (positivity lag and symptom lag) 7 . That is, it could be argued that the temporal sequence of household infections reflects the time of testing (or detection), but not necessarily the time of infection, especially when these are close (i.e., the index infection and the additional infection are actually reversed). This could be of importance, as we analyzed the vaccination status of the "additional" infection given confirmed exposure. Therefore, this final analysis examined household members who shared the same vaccination status, referred to hereinafter as homogeneously vaccinated couples. This method eliminates the need to determine the order of infections within a given household, as the status of the additional infection is identical to that of the index infection, therefore, the analyzed scenario is one where exposure certainly occurredand vaccine protectiveness is examined in either the 'index' or 'additional' household member. Confidence intervals for binomial probability were calculated, based on Wilson's score interval. All statistics were performed using Python version 3.1 with the stats models package. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259579 doi: medRxiv preprint The study protocol was approved by the MHS Institutional Review Board (033-21-MHS). Informed consent was waived by the IRB, as all identifying details of the participants were removed before computational analyses. From December 20, 2020 to March 17, 2021, data were available for 1,312,372 households that Mean age of all adult household members was 58.9 (SD -13.5), as aged increased with the likelihood of being vaccinated. Females constituted roughly 50% (Table 1) . Age and gender of participants by vaccination groups are shown in Supplementary Tables S1 and S3. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259579 doi: medRxiv preprint We assessed additional infection rates and vaccine effectiveness among household members of All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259579 doi: medRxiv preprint The probability of being tested after being exposed and its effect on estimated vaccine As expected, the probability of being tested was lower when the additional household member was a fully vaccinated individual. We calculated corrected effectiveness rates, assuming that untested individuals were as likely to be infected as tested ones -thereby estimating lower bound efficiency (see methods). The corrected effectiveness of Fully Vaccinated compared to Unvaccinated individuals was 72.0% (95% CI-65.2 to 77.5) and 73.0% (95% CI-66.0 to 78.5) when Unvaccinated was compared to Recently Vaccinated Once participants. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In order to address the problem of defining an "index" infection as opposed to an "additional" infection, we analyzed vaccine effectiveness rates among household members who share the same vaccination status when tested (homogeneously vaccinated couples, see methods). (Table 3) . Demographic data of these couples can be seen in Supplementary Table S3. Using this approach, vaccine effectiveness in fully vaccinated individuals was 74.8% (95% CI-65.4 to 81.6) when compared to unvaccinated ones, and 77.7% (95% CI-69.0 to 83.9) when compared to participants recently vaccinated once. Addressing the probability to be tested by implementing the same method described above yields Table S4 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. exposure has yet been established, though it derives important policy implications, such as the need for self-quarantine when exposed and lockdown policies in high-risk areas. In this large cohort, we examined household contacts of confirmed COVID-19 patients, therefore utilizing the microenvironment of the household to best ensure exposure, after which we analyzed vaccine effectiveness. 7.5% of fully vaccinated individuals, who are household members of confirmed COVID-19 patients were infected within ten days. Infection rates among unvaccinated or those who received only one vaccine dose within seven days were much higher at 37.5% and 41.7%, respectively. These figures translate into vaccine effectiveness rates of 80.0% and 82.0% when fully vaccinated persons were compared to participants who were either unvaccinated, or vaccinated only once within seven days of the index infection. While these rates are somewhat lower than vaccine effectivness rates in the original BNT162b2 randomized controlled trial, and vaccine effectiveness rates observed in a large representative sample of the Israeli population 8 , the degree of protection afforded by the vaccine is still very high, even in this very high-risk exposure scenario. These relatively high effectiveness rates following a high-risk exposure are encouraging news both for the individuals who choose to be All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. The present study was designed to fill a few gaps in existing data. Firstly, we included persons who were all definitely exposed to SARS-CoV-2 (potentially in the community and definitely in their household), and had an extremely high-risk of being infected. Secondly, we performed secondary analyses correcting for a possible selection bias that stems from the different likelihood of persons to be tested for COVID-19, depending on their vaccination status. In these non-RCT, real-world, scenarios, those not tested are often asymptomatic, or only mildly symptomatic [16] [17] [18] . The probability of testing contacts in Israel during the study period were generally very high (79.4%, 85.3% and 57.2% in the three vaccination status groups in this trial). Therefore, although structured screening was not performed, the high testing rates coupled with the correction performed for the differing testing rates in the three study groups, enable us to estimate with a high degree of confidence vaccine effectiveness for COVID-19 that is not All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259579 doi: medRxiv preprint necessarily severe and often asymptomatic -thus allowing for a real-world vaccine effectiveness analysis not previously performed. Our study has several limitations. All data are observational, therefore testing was not performed with the use of a strict clinical protocol. Therefore, testing was less likely to be performed for vaccinated household members and asymptomatic cases may have been missed. We did not include data on viral strains. We assumed that all exposure within a given household posed a high risk of transmission, but we are unable to quantify the actual level of exposure with a given household. The large sample size, high vaccination rates, high testing rates, and correction performed for missing testing all partly overcome these limitations. Household studies are certainly an efficient way of assessing vaccine effectiveness in a given population 6, [19] [20] [21] [22] , allowing for analyses of infection rates when exposure is confirmed with a high degree of certainty -thus avoiding the potential skewing effect of intrinsic differences amongst communities. Additionally, there is a high likelihood that the same SARS-CoV-2 strain infected persons living in the same household. Two issues are the subject of our future research, currently underway; first, the inclusion of more than two household members in general and of children in particular. Transmission dynamics could be influenced by age, and children are more likely to be asymptomatic and less likely to be tested. Children may also affect of the magnitude of exposure as they increase the number of persons per household 12 . "Quantifying" exposure relative to vaccine protectiveness, that is whether being exposed to more than one infected individual can influence vaccine effectiveness, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259579 doi: medRxiv preprint is a complicated question to answer from observational real-world data, which is often incomplete. Secondly, in this study, we have not accounted for the vaccination status of the index case. Our upcoming study attempts to create a model accounting for the possible transmission potential of the index case (rather than solely the susceptibility potential of household members). This study shows that the mRNA BNT162b2 vaccine is highly effective in a very high-risk, real life, scenario, but the protection rates afforded in these settings are somewhat lower than those previously described in an RCT or a population-based study. Household members of COVID-19 patients, those caring for them in the healthcare setting, and any other individuals with a confirmed exposure to a COVID-19 patient, are still at risk of being infected 20 even if fully vaccinated, and should use personal protection measures if possible. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259579 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259579 doi: medRxiv preprint 28 Figure S1 . Probability of the second adult in the household to be tested within 10 days of the index infection -cumulative rates of PCR tests among homogenous couples. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259579 doi: medRxiv preprint COVID-19 in 2021-Continuing Uncertainty Factors that make an infectious disease outbreak controllable Factors Associated with Participation in Elementary School-Based SARS-CoV-2 Testing -Salt Lake County Transmission of SARS-COV-2 Infections in Households -Tennessee and Wisconsin Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study Household studies provide key insights on the transmission of, and susceptibility to, SARS-CoV-2 No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted The incubation period of coronavirus disease 2019 (CoVID-19) from publicly reported confirmed cases: Estimation and application BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting COVID-19 in Israel dashboard Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis Title: Decreased SARS-CoV-2 viral load following vaccination COVID-19 in Children, Pregnancy and Neonates: A Review of Epidemiologic and Clinical Features Available All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2. Science (80-) Update Alert 3: Masks for Prevention of Respiratory Virus Infections, Including SARS-CoV-2, in Health Care and Community Settings A systematic review of asymptomatic infections with COVID-19 Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility Household transmission of 2009 pandemic influenza A (H1N1): A systematic review and metaanalysis Available All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Probable secondary infections in households of SARS patients in Hong Kong Household transmission of COVID-19-a systematic review and meta-analysis No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted